CPD Login
Atrial fibrillation and stroke
At the recent Cardiology 2021 Virtual Symposium, themed around the important topic of atrial fibrillation and stroke, five thought leaders…
REWINDING REWARD in the management of type 2 diabetes
SGLT2-inhibitors have a major beneficial effect on reducing heart failure
Specialist Forum October 2021 issue CPDs
Below you will find links to CPD articles produced for Specialist Forum‘s October 2021 issue.
Preventing sudden death in patients with heart failure
Sudden cardiac death is the main cause of mortality in 30% to 50% of patients with heart failure with reduced…
Legacy effects of fibrate add‑on therapy in diabetic patients with dyslipidaemia
There are ‘legacy effects’ of fibrate add-on therapy on cardiovascular outcomes in patients with dyslipidaemia.
What is the optimal treatment for HF?
Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals. In South Africa, HF…
Specialist Forum July 2021 CPDs
Below you will find links to CPD articles produced for Specialist Forum‘s July 2021 issue.
Heart failure redefined
Three international cardiology societies have joined forces to develop a new universal definition and classification of heart failure (HF).1
Diabetic nephropathy complexities
Hypertension is common among patients with diabetes. Hypertension increases their risk of chronic kidney disease (CKD) onset and progression, as…
Efficacy of fixed-dose, triple therapy in essential hypertension
Hypertension is the leading cause of mortality worldwide, accounting for more than 10 million deaths every year. The majority of…
ACS one of the leading causes of disability in people of all ages
Ischaemic heart disease – now referred to as acute coronary syndrome (ACS) –is ranked second after neonatal disorders as the…
7 key messages from the ECS about adult CHD
Although the prevalence of severe congenital heart defects (CHD) is declining worldwide, the overall prevalence – especially in adult patients…
Sanofi and Regeneron announce approval of alirocumab for the treatment of hypercholesterolaemia in SA
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the South African Health Products Regulatory Agency (SAHPRA) has approved alirocumab for…
Acquired haemophilia: Rare, but fatal
Acquired haemophilia A (AHA) – also known as acquired factor VIII inhibitor disorder – is a rare bleeding condition (one…
Increased cardiovascular residual risk in patients with diabetes due to atherogenic dyslipidaemia
Cardiovascular disease (CVD) and type 2 diabetes (T2DM) is on the increase worldwide and clinicians need to be aware of…
